| Date Filed | Type | Description |
| 08/16/2023 |
SC 13G
| Stonepine Capital Management, LLC reports a 5.8% stake in IO Biotech, Inc. |
| 08/15/2023 |
SC 13G/A
| HBM Healthcare Investments Ltd. reports a 8.2% stake in IO Biotech, Inc. |
| 08/14/2023 |
SC 13G/A
| HBM Healthcare Investments Ltd. reports a 6.1% stake in IO Biotech, Inc. |
| 08/14/2023 |
SC 13D/A
| Lundbeckfond Invest A/S reports a 29.6% stake in IO Biotech, Inc. |
| 08/11/2023 |
SC 13D/A
| Novo Holdings A/S reports a 12% stake in IO Biotech, Inc. |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Form of Warrant",
"Securities Purchase Agreement, by and among the Company and the Purchasers",
"Registration Rights Agreement, by and among the Company and the Purchasers",
"IO Biotech, Inc. Announces $75 Million Private Placement Financing • Offering includes participation from both new and existing healthcare-dedicated investors. • Proceeds extend the company's cash runway into the fourth quarter of 2025 NEW YORK, August 7, 2023 - IO Biotech, Inc. , a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $75 million, before deducting offering expenses. The private placement includes participation from new and existing investors, including Lundbeckfonden BioCapital; Kurma Growth Opportunities Fund; Vivo Capital; Armisti...",
"Corporate Presentation" |
|
| 07/18/2023 |
8-K
| Quarterly results |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/14/2023 |
8-K
| Quarterly results |
| 03/14/2023 |
8-K
| Investor presentation |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 3.9% stake in IO Biotech, Inc. |
| 02/14/2023 |
SC 13G/A
| PFM Health Sciences, LP reports a 1.8% stake in IO Biotech, Inc. |
| 02/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/13/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/03/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/13/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/30/2022 |
SC 13D/A
| Novo Holdings A/S reports a 11.4% stake in IO Biotech, Inc. |
| 08/11/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|